West Pharmaceutical Services (WST) Other financing activities (2009 - 2026)

West Pharmaceutical Services (WST) has reported Other financing activities for 18 consecutive years, with $6.9 million the latest figure, recorded in Q2 2026.

• Quarterly Other financing activities rose 97.14% year-over-year to $6.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $17.7 million (up 52.59% YoY) and the FY2025 annual result came in at $11.3 million, down 55.69% from the prior year.
• Other financing activities improved to $6.9 million in Q2 2026 per WST's latest filing, from $5.5 million in the prior quarter.
• Over the last five years, Other financing activities for WST reached as high as $18.6 million in Q3 2023 and fell as low as $1.3 million in Q4 2023.
• A 5-year average of $6.3 million and a median of $4.8 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2023 — Other financing activities jumped 190.62% — and 2025, when it tumbled 83.11%.
• Year by year, Other financing activities stood at $3.8 million in 2022, then tumbled by 65.79% to $1.3 million in 2023, then climbed by 15.38% to $1.5 million in 2024, then jumped by 106.67% to $3.1 million in 2025, then soared by 122.58% to $6.9 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $6.9 million, $5.5 million, and $3.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.